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ABSTRACT
Objective To determine the efficacy of a probiotic drink
containing Lactobacillus for theprevention of any diarrhoea
associated with antibiotic use and that caused by
Clostridium difficile.
Design Randomised double blind placebo controlled
study.
Participants 135 hospital patients (mean age 74) taking
antibiotics. Exclusions included diarrhoea on admission,
bowel pathology that could result in diarrhoea, antibiotic
use in the previous four weeks, severe illness,
immunosuppression, bowel surgery, artificial heart
valves, and history of rheumatic heart disease or infective
endocarditis.
Intervention Consumption of a 100 g (97 ml) drink
containing Lactobacillus casei, L bulgaricus, and
Streptococcus thermophilus twice a day during a course of
antibiotics and for oneweek after the course finished. The
placebo group received a longlife sterile milkshake.
Main outcome measures Primary outcome: occurrence of
antibiotic associated diarrhoea. Secondary outcome:
presence of C difficile toxin and diarrhoea.
Results 7/57 (12%) of the probiotic group developed
diarrhoea associated with antibiotic use compared with
19/56 (34%) in the placebo group (P=0.007). Logistic
regression to control for other factors gave an odds ratio
0.25 (95% confidence interval 0.07 to 0.85) for use of the
probiotic, with low albumin and sodiumalso increasing the
risk of diarrhoea. The absolute risk reduction was 21.6%
(6.6% to 36.6%), and the number needed to treat was 5
(3 to 15). No one in the probiotic group and 9/53 (17%) in
the placebo group had diarrhoea caused by C difficile
(P=0.001). The absolute risk reduction was 17% (7% to
27%), and the number needed to treat was 6 (4 to 14).
Conclusion Consumption of a probiotic drink containing L
casei, L bulgaricus, and S thermophilus can reduce the
incidence of antibiotic associated diarrhoea andCdifficile
associated diarrhoea. This has the potential to decrease
morbidity, healthcare costs, and mortality if used
routinely in patients aged over 50.
Trial registration National Research Register
N0016106821.
INTRODUCTION
There is increasing evidence that probiotics are bene-
ficial in a range of gastrointestinal conditions, includ-
ing infectious diarrhoea and that related to antibiotic
use.1 Probiotics are defined as “live micro-organisms
which when administered in adequate amounts confer
a health benefit on the host”2 and include Streptococcus
thermophilus, Enterococcus species, Saccharomyces species,
and various species of lactobacilli and bifidobacteria.
Diarrhoea associated with antibiotic use and caused
by Clostridium difficile is a complication of treatment
with antimicrobial agents and occurs in about 5-25%of
patients.3C difficile is responsible for around 15-25% of
all cases of diarrhoea associated with antibiotic use,
most occurring in older patients, usually in the two to
three weeks after cessation of antibiotic treatment.4
Lactobacilli, bifidobacteria, and Streptococcus species
have all been evaluated for the prevention or treatment
of diarrhoea associatedwith antibiotic use and found to
be safe.5 Several reviews support benefit but still call
for large placebo controlled trials to determine species
and dose effectiveness for prevention, to show effec-
tiveness in preventing diarrhoea caused by C difficile,
and to establish effect on length of hospital stay and
cost effectiveness.6-8
We undertook a randomised double blind, placebo
controlled trial of a commercially available probiotic
preparation in older patients in hospital who were
receiving antibiotics.
METHODS
The hypothesis was that a probiotic Lactobacillus pre-
paration would reduce the incidence of antibiotic asso-
ciated diarrhoea and C difficile associated diarrhoea.
Our primary outcome was the occurrence of diar-
rhoea, which was recorded by the nursing staff and
authenticated by the researchers. Diarrhoea was
defined as more than two liquid stools a day for three
or more days in quantities in excess of normal for each
patient. The secondary outcome was the occurrence of
C difficile infection, defined as an episode of diarrhoea
combined with the detection of toxins A or B, or both,
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from a stool sample (enzyme immunoassay kit, Meri-
dian Bioscience, OH, USA).
Participants
We recruited patients from three London hospitals:
Hammersmith, Charing Cross, and Hillingdon.
Patientswere recruitedmainly fromorthopaedic,med-
ical, and care of the elderly wards, and included inpa-
tients aged over 50 who were prescribed antibiotics
(single or multiple antibiotics, oral or intravenous)
and were able to take food and drink orally. Initially
patients had to be able to give written informed con-
sent, though half way through the trial we received
ethical approval to recruit patients with cognitive
impairment. Nevertheless, only seven patients had an
abbreviated mental test score9 less than 7 (four in the
control group and three in the probiotic group).
Our exclusion criteria were diarrhoea on admission
or within the preceding week, reported recurrent diar-
rhoea, or bowel pathology that could result in diar-
rhoea; intake of high risk antibiotics (clindamycin,
cephalosporins, aminopenicillins) or more than two
courses of other antibiotics in the past four weeks to
exclude pre-existing diarrhoea associated with anti-
biotic use; severe life threatening illness, immunosup-
pression, bowel surgery, artificial heart valve, history
of rheumatic heart disease, or history of infective endo-
carditis5; regular probiotic treatment before admis-
sion; and lactose intolerance or intolerance to dairy
products.
Interventions
The treatment group received a probiotic yoghurt
drink (Actimel, Danone, France) containingLactobacil-
lus caseiDN-114 001 (L casei imunitass) (1.0×108 colony
forming units/ml), S thermophilus (1.0×108 cfu/ml), and
L bulgaricus (1.0×107 cfu/ml). The placebo group
received a longlife, sterile milkshake (Yazoo, Cam-
pina, Netherlands). We carried out general lactobacil-
lus counts on a sample of the probiotic drinks to ensure
they were active. L casei imunitass has been shown to
travel through the humangut and survive into the large
intestine,10 thus meeting one criterion of a probiotic.
Participants began using the drinks within 48 hours of
starting antibiotic therapy and continued doing so for
one week after they stopped taking antibiotics. They
drank 100 g (97 ml) twice daily half an hour before or
one to two hours after meals. Researchers verified par-
ticipants’ consumption and recordedmissedor refused
drinks to assess compliance.
Study plan
The admitting medical team identified potential
patients who had been prescribed antibiotics and the
researchers approached them within 48 hours of the
first antibiotic dose.Once they obtained informed con-
sent, they collected baseline data and prescribed the
randomised study drink. The hospital pharmacy dis-
pensed thedrink.Abaseline stool samplewas collected
to screen for asymptomatic C difficile carriage. Bowel
movements were monitored with stool charts, which
were checked every weekday for accuracy. When
there was evidence of diarrhoea a stool sample was
analysed for C difficile toxin.
Once the antibiotic course was finished a final week
of study drink was dispensed and a final follow-up date
fixed for four weeks later. Patients who were dis-
charged taking antibiotics were provided with enough
drink on discharge to cover the period they had to take
antibiotics plus one week. Researchers followed up
participants for four weeks fromdischargewithweekly
phone calls to ask about diarrhoea and compliance. If
participants had diarrhoea, the researchers collected a
further stool sample to check for C difficile toxin.
Sample size
With α=0.05 and a power of 90% to detect an absolute
difference of 20% between the proportion of patients
with antibiotic associated diarrhoea in the placebo
(assumed at 30%) and probiotic (assumed at 10%)
groups we estimated that we needed a sample size of
164 (82 in each group).
Randomisation
An independent statistician generated the randomallo-
cation sequence, which was stratified for hospital, sex,
and two age groups (50-69 and ≥70). The sequencewas
given to the pharmacy on each site.
Blinding
Actimel is sold in 100 gwhite plastic bottles with remo-
vable labels; Yazoo is packaged similarly but in 200ml
bottles. We chose Yazoo as placebo because it looks
identical in colour and consistency to Actimel but is
an ultra high temperature treated product and has no
Assessed for eligibility (n=1760)
Enrolment (n=135)
Placebo group (n=66):
  Consumed > 50% of drink (n=59)
  Consumed <50% of drink (n=7, all still
    continued on trial and are included in
    data analysis)
Probiotic group (n=69):
  Consumed > 50% of drink (n=61)
  Consumed <50% of drink (n=8, all still
    continued on trial and are included in
    data analysis)
Allocation
Excluded (n=1625)
  Not meeting inclusion criteria (n=1263)
  Refused to participate (n=148)
  Could not be screened, aiming for next day discharge, moved to private ward, unlikely
   to comply with study protocol, readmissions who had already taken part (n=214)
Lost to follow-up (n=10):
  Unable to contact after discharge home,
    therefore no data on diarrhoea
    incidence (n=8)
  Withdrew consent (n=2)
Lost to follow-up (n=12):
  Unable to contact after discharge home,
    therefore no data on diarrhoea
    incidence (n=8)
  Withdrew consent (n=3)
  Died (n=1) 
Follow-up
Analysed for occurrence of diarrhoea (n= 56)Analysed for occurrence of diarrhoea (n=57) Analysis
Flow chart showing numbers of patients at each stage of the trial
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bacterial content. The pharmacies removed the com-
mercial labels, then applied study labels to identify the
patient, the drink’s “use by” date, and storage instruc-
tions.We could not find a placebo in an identical bottle
to Actimel.
Patients and researchers were blind to the study
drink as they did not see the bottle the drink came in.
Nursing staff dispensed the drinks and were instructed
to pour 100ml into a cup for the patient; they were not
told which bottle contained which drink. Older people
in the UK are not generally familiar with these pro-
ducts, but it is possible somepatientsmight have recog-
nised the taste.However, we had excluded peoplewho
regularly took this or other probiotic products from the
study.
Potential bias through unblinding was possible but
unlikely, and the outcome measure was checked and
agreed between two or more people. Microbiology
staff who were blind to the study grouping assessed
occurrence of C difficile by analysis of a stool sample
from patients who had diarrhoea.
Statistical methods
We used Fisher’s exact test to compare rates of anti-
biotic associated diarrhoea and C difficile associated
diarrhoea and logistic regression (block entry with
removal of non-significant variables) to establish
which factors influenced the occurrence of diarrhoea
and to estimate the adjusted odds ratio for treatment
effect.
RESULTS
From November 2002 to January 2005, 135 patients
entered the study (figure). The most common reason
for exclusion (61% of patients) was the likelihood of
diarrhoea from causes unrelated to antibiotics. A
further 21% of patients were excluded because of pos-
sible safety concerns, and 18% were not able to give
informed consent nor were relatives willing or avail-
able to give assent. Only one patient was excluded
because of a dairy allergy.
Therewere no reported adverse events related to the
study drinks. In the 24 samples we tested for lactoba-
cillus the mean count was 2.2×108 cfu/ml (range
0.35×108-4.6×108). We found no bacterial content in
the Yazoo samples.
There were no clinically important differences
between the two groups at baseline (table 1). Most
patients received one antibiotic, but about 40%
received two (table 1). The most common reasons for
antibiotic use were respiratory infection (49%) or pro-
phylaxis before or after surgery (25%) (usually ortho-
paedic). Compliancewas assessed by the percentage of
prescribed drinks that were consumed: 75% (inter-
quartile range 55-91%) of the probiotic and 79% (63-
94%) of the control drink. Themain reason for compli-
ance rates falling below 100%were delivery and distri-
bution failures, rather than palatability. One patient in
each group was positive for C difficile toxin at baseline
but had no diarrhoea; neither patient subsequently
developed diarrhoea.
The primary analysis was intention to treat and
included all patients with available end point data
(table 2). We could not complete follow-up on 16%
(22/135; 12 in probiotic group, 10 in placebo group)
as we were unable to contact them at home despite
numerous phone calls and written communications
(16) or they had withdrawn (6) from the study, thus
the analysis for occurrence of antibiotic associated
diarrhoea included 113 patients (56 in control and 57
in probiotic group). Four patients were not tested for C
difficile (one in probiotic group, three in control group)
and thus were not included in the analysis for occur-
rence of diarrhoea associated withC difficile.We found
a significant reduction in both the incidence of anti-
biotic associated diarrhoea (P=0.007) and C difficile
associated diarrhoea (P=0.001) in the probiotic
group. The absolute risk reduction for occurrence of
antibiotic associated diarrhoea was 22% (95% confi-
dence interval 7% to 37%), and the number needed to
Table 1 | Baseline characteristics of study participants. Figures are numbers (percentages) of
patients unless stated otherwise
Probiotic (n=69) Control (n=66)
Women 39 (57) 34 (52)
White European 61 (88) 59 (89)
Mean (SD) age (years) 73.7 (11.1) 73.9 (10.5)
Median (IQR) BMI 25.5 (20.6-31.5) 23.7 (19.7-30.5)
Mean (SD) albumin (g/l) 33.2 (5.3) 32.7 (6.1)
Median (IQR) white cell count (/l) 9.0 (6.8-13.3) 9.5 (7.0-13.1)
Median (IQR) plasma sodium (mmol/l) 138.0 (135-140) 137.0 (135-139)
Median (IQR) C reactive protein (mg/l) 37.0 (13.0-118.0) 46.0 (15.8-140.0)
Median (IQR) thyroid stimulating hormone (mU/l) 1.17 (0.56-2.09) 0.9 (0.6-1.74)
Median (IQR) thyroxine (pmol/l) 15.5 (14.0-17.2) 15.3 (13.0-16.7)
Median (IQR) length of stay (days):
Before randomisation 1.0 (1.0-2.0) 1.0 (1.0-2.0)
After randomisation 9.0 (5.0-16.0) 8.0 (4.5-14.0)
Alcohol drinkers 34 (49) 33 (50)
Median (IQR) alcohol units/week in drinkers 6 (2-12) 9 (3-21)
Smokers 19 (28) 11 (17)
Mean (SD) No of cigarettes/week in smokers 82 (66) 102 (87)
No of antibiotics prescribed:
1 40 (58) 34 (52)
2 26 (38) 29 (44)
3 3 (4) 3 (5)
Risk of antibiotic causing diarrhoea*:
Low 0 (0) 1 (1.5)
Medium 26 (38) 19 (29)
High 43 (62) 46 (70)
Indication for antibiotics:
Respiratory tract infection 33 (48) 33 (50)
Prophylaxis before/after surgery 17 (25) 17 (26)
Urinary tract infection 10 (15) 10 (15)
Other† 7 (10) 5 (8)
Missing 2 (3) 1 (2)
IQR=interquartile range; BMI=body mass index.
*Low risk=metronidazole and parenteral aminoglycosides (gentamicin); medium risk=tetracyclines
(oxytetracycline), sulphonamides (trimethoprim), macrolides (azithromycin, clarithromycin, erythromycin),
quinolones (ciprofloxacin); high risk=aminopenicillin (amoxicillin, benzylpenicillin, co-amoxiclav, flucloxacillin),
cephalosporins (cefalexin, ceftazidime, cefuroxime).11
†Cellulitis (5), ulcer (2), pressure sore (1), sepsis (1), sore throat (1), cholecystitis (2).
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treat was 5 (3 to 15). For C difficile associated diarrhoea
the figures were 17% (7% to 27%) and 6 (4 to 14).
Tables 3 shows the result of logistic regression of
antibiotic associated diarrhoea as the dependent vari-
able with treatment group, age, sex, indication for anti-
biotics, number of antibiotics, smoking, alcohol
consumption, body mass index, serum albumin, thyr-
oxine, white cell count, C reactive protein, and plasma
concentrations of creatinine, potassium, and sodiumas
covariates. Every 1 g/l increase in albumin concentra-
tion was associated with an 18% reduction in the odds
of diarrhoea, and every 1 mmol/l increase in sodium
concentration was associated with a 16% reduction.
After adjustment for these variables the probiotic treat-
ment reduced the odds of diarrhoea by 75%. The small
number of cases ofCdifficile associateddiarrhoeamade
logistic analysis inappropriate.
Additional information is available on bmj.com.
DISCUSSION
Twice daily intake of a probiotic drink containing L
casei, L bulgaricus, and S thermophilus for one week
longer than the duration of antibiotic treatment can
prevent diarrhoea associated with antibiotic use and
that caused byC difficile. There were no adverse events
and the drink was well accepted. This is a major
advance on previous meta-analyses, which called for
further definitive trials and expressed considerable
doubt as to the efficacy in preventing C difficile asso-
ciated diarrhoea.6-8
Strengths and weaknesses
This study was adequately powered for the large treat-
ment effect in antibiotic associated diarrhoea and used
a probiotic freely available in theUK.Additionally, we
were able to show the bacterial content of the product,
included a four week absence of antibiotic use before
enrolment, and tested for C difficile toxin in all patients
with diarrhoea.
In vitro studies have shown that different bacterial
strains work differently,12 and previous trials have pro-
duced conflicting results13-19; thus other strainsmaynot
produce the same beneficial effect as the strains tested
here.We could not establishwhich bacteria species are
effective from the three strains in this probiotic drink;
the three speciesmaybeworking synergistically to pre-
vent diarrhoea or alternatively one species may be
more effective than another. Therefore, our results
cannot be extrapolated to other probiotic products,
which must be tested in similar trials.20
An obvious methodological weakness is the possibi-
lity of unblinding of the researchers and patients. We
did, however, take precautions to avoid unblinding
and, most importantly, several people confirmed the
presence of diarrhoea. The loss to follow-up of 16%
of the study population is also a weakness, though the
numbers lost in each group were similar (12 in the pro-
biotic group and 10 in the control group) and should
not significantly alter the results.
The figure illustrates the difficulties in recruitment
for this study; of 1760 patients screened only 135
took part. This raises questions about whether the
results are generalisable. Some patients were excluded
to prevent inclusion of diarrhoea from other causes
and some patients were excluded because of a lack of
informed consent; these factors are irrelevant in rou-
tine use and amounted to 79%of exclusions in this trial.
Others were excluded to ensure safety, and 21% were
excluded on these grounds. Infections such as endo-
carditis or bacteraemia are rare, and recent safety
reviews have questionedwhether probioticswere actu-
ally the cause of infection in some documented cases.5
Nevertheless,wewere cautiouswhen recruiting for this
study. Such strict criteria, however,may not be needed
in practice. The high refusal rate (148) is unsurprising
as we were approaching mainly elderly patients early
in their hospital stay. The need for extensive data col-
lection, monitoring, and collection of stool samples
will certainly have discouraged some patients. Should
probiotics become routinely used in hospitals patients
are far more likely to accept it as an established rather
than a trial treatment. Thus, we think the results can be
generalised to anyolder patients in hospital, taking into
account safety concerns for specific patients.
Costs
Using the numbers needed to treat (5 for antibiotic
associated diarrhoea, 6 for C difficile associated diar-
rhoea) we calculated the cost to prevent one case of
antibiotic associated diarrhoea. The estimated average
cost of the probiotic was £10 (€14.8; $20) per patient
(assuming an average antibiotic course of 10 days plus
a further seven days of probiotics, and using current
retail prices for Actimel, about £0.30 (€0.44; $0.60)
each). The cost to prevent one case would therefore
be £50 (€74; $100) for antibiotic associated diarrhoea
Table 2 | Total number of cases of antibiotic associated
diarrhoea (including cases positive for C difficile) and
proportionwhowere positive or negative for C difficile toxin
(all patients followedup in hospital and after discharge)
Probiotic Control P value*
Diarrhoea
Yes 7 (12) 19 (34)
0.007
No 50 (88) 37 (66)
No of patients 57† 56†
C difficile toxin
Positive 0 9 (17)
0.001
Negative 56 (100) 44 (83)
No of patients 56‡ 53‡
*Fisher’s exact test.
†22/135 patients lost to follow-up or withdrew.
‡4/113 patients not tested for C difficile.
Table 3 | Riskmodel for prediction of antibiotic associated
diarrhoeawith logistic regression
Odds ratio (95% CI)
Treatment (probiotic=0, placebo=1) 0.25 (0.07 to 0.85)
Plasma sodium 0.84 (0.75 to 0.95)
Serum albumin 0.82 (0.73 to 0.92)
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and £60 (€89; $120) forC difficile associated diarrhoea,
excluding dispensing and nursing costs. Evidence sug-
gests that additional treatment costs per patient for C
difficile associated diarrhoea are on average $3669
(£1835; €2738) in the United States21 and £4000
(€5920; $8000) in the United Kingdom22, mainly
because of increased length of stay in hospital but
also because of the use of vancomycin. Clearly sub-
stantial savings could be made by the routine use of
probiotics.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Probiotics may prevent diarrhoea associated with antibiotics and Clostridium difficile
Adequately powered, double blind randomised controlled trials are needed to assess the
efficacy of specific probiotic strains
Evidence for the efficacy of probiotic products readily available in the UK is lacking
WHAT THIS STUDY ADDS
Consumption of a readily available probiotic drink containing Lactobacillus casei, L
bulgaricus, and Streptococcus thermophilus, twice a day during a course of antibiotics and
for one week afterwards, reduces the incidence of diarrhoea associated with antibiotic use
and C difficile
Compliance with the probiotic drink was good
The cost to prevent one case of diarrhoea was £50 (€74; $100) and £60 (€87.5; $120) to
prevent one case of C difficile
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